Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin  G. Drusano  Clinical Microbiology and Infection 

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

R. Leclercq  Clinical Microbiology and Infection 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period  J. Liñares, C. Ardanuy, R. Pallares, A.
Gut bacterial microbiota and obesity
D. Khalil, M. Hultin, M.U. Rashid, B. Lund 
P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys 
Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources  N. Singh,
Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis  A. Hedberg,
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
R. Cantón  Clinical Microbiology and Infection 
A.E. Muller, U. Theuretzbacher, J.W. Mouton 
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program  M.
Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia  C. Carbon, S. Moola,
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
D.E. Low  Clinical Microbiology and Infection 
Vector control: a cornerstone in the malaria elimination campaign
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations  D. Andes, W.A. Craig  Clinical Microbiology.
Oral versus intravenous therapy in the treatment of systemic mycosis
Training for the infectious diseases speciality in Norway
Community-acquired pneumonia: the evolving challenge
The use and therapeutic drug monitoring of teicoplanin in the UK
B. Gordts  Clinical Microbiology and Infection 
CMI editorial report 2011 Clinical Microbiology and Infection
Z. Wang, Z. Cui, Y. Li, T. Hou, X. Liu, Y. Xi, Y. Liu, H. Li, Q. He 
Bacterial resistance—the clinical challenge
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Elements of design: the knowledge on which we build
Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan  P.-R. Hsueh, J.-M. Shyr, J.-J. Wu  Clinical.
Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Levofloxacin in the treatment of ventilator-associated pneumonia
Metagenomics and probiotics
Effect of antioxidants on the immune response of Helicobacter pylori
Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin  King A. , Bathgate.
B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas 
W.A. Craig  Clinical Microbiology and Infection 
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
Symposia and Oral Presentations
A. Bryskier  Clinical Microbiology and Infection 
J. Garau  Clinical Microbiology and Infection 
T.M. File  Clinical Microbiology and Infection 
Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union  S. Bronzwaer  Clinical.
Antibacterial drug discovery in the 21st century
Grepafloxacin: pharmacokinetics and tissue penetration
Abstracts cont. Clinical Microbiology and Infection
Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis  S.R. Norrby, J. Quinn, M. Rangaraju,
P.M. Hawkey  Clinical Microbiology and Infection 
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci  H.L. DuPont, Z.-D. Jiang  Clinical Microbiology.
Reducing antibiotic use in influenza: challenges and rewards
Fibronectin concentrations in catheter sepsis
Antimicrobial drug development – the past, the present, and the future
An after-hours clinical liaison blood culture service—is it worth it?
Clinical Microbiology and Infection
Structure–activity relationships of ketolides vs. macrolides
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
Overview of cefixime use in community-acquired infections
The atypical pneumonias: clinical diagnosis and importance
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Joshua P. Metlay, Daniel E. Singer  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin  G. Drusano  Clinical Microbiology and Infection  Volume 7, Pages 24-29 (January 2001) DOI: 10.1046/j.1469-0691.2001.0070s3024.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 1 Plasma concentration-time profile of telithromycin after single and 10 days' once-daily administration of 800 mg to 12 healthy young subjects [12]. ery-R, erythromycin resistant; ery-S, erythromycin susceptible; peni-R, penicillin resistant; LOQ, limit of quantification. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 2 Telithromycin plasma concentration-time profile following an oral 800 mg dose of telithromycin taken after either an overnight fast or a standard high-fat breakfast [14]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 3 Mean concentration of telithromycin in epithelial lining fluid (ELF) and plasma following telithromycin 800 mg once daily for 5 days in 24 healthy volunteers [17]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions